Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-184

This is a classic PIVOT story. READ BETWEEN THE LINES.

The irony is that they believe the new indication will likely be a very successful market for them and worth Pursuing above the current IIH trajectory. I think, given they can effectively skip the que with safety trials, that a pivot is being signalled by the company as a preferred direction.

The secondary indication was being Pursued AS the trial was failing. They saw the writing on the wall. As soon as it was approved, they spilled the beans. Short term pain for LT gain.

There will be a spill, a CEO change and new direction.

I believe, that in the future, this will be seen as a master stroke.